低血糖的发展状况和研究进展:一篇综述
Wenxue Zhao1, Xinhe Zhao1, Yanan Li2
1College of Agricultural Engineering and Food Science, School of Materials Science and Engineering, Shandong University of Technology, Zibo, 255000, China.
International journal of biological macromolecules
|December 25, 2025
概括
低血糖是传统糖尿病治疗的有希望的替代品,因为它们具有强大的活性和较少的副作用. 研究探讨了它们的机制,应用以及在医学和功能性食品中的未来潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 食品科学 食品科学 食品科学
背景情况:
- 糖尿病是一种代谢障碍,其特征是高血糖.
- 低血糖是一种生物活性,具有治疗2型糖尿病的潜力.
- 这些与小分子药物相比具有优势,包括明确的机制和较低的毒性.
研究的目的:
- 审查低血糖的来源,制备,分析和净化.
- 专注于这些的生理功能,作用机制和结构.
- 总结临床和临床前应用,并探索食品和医药的未来潜力.
主要方法:
- 关于低血糖的现有研究的文献综述.
- 分析结构及其与降糖效应的相关性.
- 关于低血糖应用的临床和临床前数据的摘要.
主要成果:
- 低血糖通过抑制诸如α-葡萄糖酶,α-氨酶和二基-4酶等关键酶来降低血糖.
- 疏水性氨基酸在其降糖作用中起作用.
- 现有的研究支持它们在医学和临床前环境中的应用.
结论:
- 低血糖显示出作为治疗剂和功能性食物在糖尿病管理方面具有显著的潜力.
- 需要进一步的研究来解决目前的局限性,并指导未来的发展.
- 这些质为新型糖尿病治疗和功能性食品开发提供了有希望的途径.
相关概念视频
Glucagon-like Receptor Agonists
816
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
816
Hypoglycemia and Glucagon
766
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
766
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.1K
Oral Hypoglycemic Agents: Glinides
560
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
560
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K
Dipeptidyl Peptidase 4 Inhibitors
547
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
547


